GPT Healthcare (NSE:GPTHEALTH) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:GPTHEALTH GPT Healthcare Ltd NSE:GPTHEALTH
43 GF Score
Price ₹147.51
! 3 Warning Signs
View Full Analysis

What is GPT Healthcare Research & Development?

GPT Healthcare NSE:GPTHEALTH -1.61% 43 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:GPTHEALTH with a GF Score™ of 43/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. GPT Healthcare's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

GPT Healthcare  (NSE:GPTHEALTH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GPT Healthcare Research & Development Related Terms

GPT Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for GPT Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GPT Healthcare Research & Development Chart

GPT Healthcare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

GPT Healthcare Quarterly Data
Mar21 Mar22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:GPTHEALTH
43GF Score
GPT Healthcare Ltd NSE:GPTHEALTH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GPT Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
GPT Healthcare (NSE:GPTHEALTH) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on GPT Healthcare and its competitors.
Is GPT Healthcare's Research & Development too high?
GPT Healthcare's current Research & Development is ₹0 Mil. Overall, GPT Healthcare has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does GPT Healthcare's Research & Development compare to HCA and THC?
GPT Healthcare's Research & Development of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on GPT Healthcare and its competitors. GPT Healthcare's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GPT Healthcare stock overvalued right now?
GPT Healthcare (NSE:GPTHEALTH) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. GPT Healthcare's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For GPT Healthcare (NSE:GPTHEALTH), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GPT Healthcare Business Description

Other Exchanges 544131:India
Address Sector III, GPT Centre, JC-25, Salt Lake, Kolkata, WB, IND, 700106
GPT Healthcare Ltd is engaged in the healthcare sector. It operates a chain of mid-sized full-service hospitals under the ILS brand. It provides integrated healthcare services, with a focus on secondary and tertiary care and operates four multispecialty hospitals in Dum Dum, Salt Lake and Howrah in West Bengal and Agartala in Tripura with a total capacity of approximately 561 beds. It offers a comprehensive range of healthcare services across over 35 specialities and super specialities, including internal medicine and diabetology, nephrology (including renal transplants), laparoscopic and general surgery, gynaecology and obstetrics, critical care, gastroenterology, orthopaedics and joint replacements, interventional cardiology, neurology, neurosurgery, paediatrics, and neonatology.
43GF Score

Get the complete analysis for NSE:GPTHEALTH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹147.51
Price